other_material
confidence high
sentiment negative
materiality 0.75
Indivior estimates $105-130M restructuring charges; exits six non-US markets
Indivior Pharmaceuticals, Inc.
- Total pre-tax restructuring charges estimated at $105-130M, with $65M recognized in Q3 2025.
- Plans to exit markets: UK, Ireland, Sweden, Israel, Finland, Italy under Action Agenda Phase I.
- Expects at least $150M annual operating expense savings starting in 2026.
- Cash portion of charges $73-92M; includes severance, real estate, asset impairments, contract terminations.
- Headcount reductions cost $33-37M; real estate consolidation $15-21M; asset impairments $21-27M.